FDA PR About-Face
This article was originally published in RPM Report
Executive Summary
A recent effort to build a new type of public affairs staff for the Food & Drug Administration may be backfiring.
You may also be interested in...
FDA Press Office Shakeup Generates Bad Headlines For Agency With Charges Of Ageism
A young FDA official’s decision to boot three seasoned press specialists from the Public Affairs Office may be an embarrassment for an agency seeking to burnish its image.
US Medicare Plans 'Can' Cover Wegovy, CMS Says, But Will They?
Medicare is making clear that Part D ‘can’ cover GLP-1 inhibitors that are approved for cardiovascular indications – but in language that seems to leave plans considerable discretion for now. The formulary review process for 2025 may be a more important milestone for changes.